Fzata Patents – Insights & Stats (Updated 2023)

Fzata has a total of 13 patents globally, out of which no patents have been granted. Of these 13 patents, more than 76% patents are active. Canada is where Fzata has filed the maximum number of patents, followed by the United States of America and Europe. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Fzata.

Fzata was founded in 2015. Fzata has a new way of making medicines that you take by mouth, and it’s called Bioengineered Probiotic Yeast Medicines (BioPYM). They have more than 10 drug options for treating conditions in the digestive system.

Do read about some of the most popular patents of Fzata which have been covered by us in this article and also you can find Fzata patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Fzata patent portfolio.

How many patents does Fzata have?

Fzata has a total of 13 patents globally. These patents belong to 3 unique patent families. Out of 13 patents, 10 patents are active.

How Many Patents did Fzata File Every Year?

Fzata Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantFzata Applications FiledFzata Patents Granted
20223
20214
20206

How many Fzata patents are Alive/Dead?

Worldwide Patents

Fzata Patent Portfolio

How Many Patents did Fzata File in Different Countries?

Fzata Worldwide Patent Filing

Countries in which Fzata Filed Patents

CountryPatent
Canada3
United States Of America2
Europe2
Australia1
Japan1
Hong Kong (S.A.R.)1

Where are Research Centers of Fzata Patents Located?

The Research Centers of Fzata Patents is the United States of America.

List of Fzata patents

Fzata PatentsTitle
US20240011985A1Neutralized Antibody And Method Of Use Thereof
US20220235120A1Humanized Tetra-Specific Octavalent Antibody Against Clostridium Difficile Toxin A And B
EP4232818A1Neutralized Antibody And Method Of Use Thereof
EP3976094A4Humanized Tetra-Specific Octavalent Antibody Against Clostridium Difficile Toxin A And B
CA3221887A1Genetically-Modified Saccharomyces Yeast Strains As Preventative And Therapeutic Agents
CA3196256A1Neutralized Antibody And Method Of Use Thereof
CA3142602A1Humanized Tetra-Specific Octavalent Antibody Against Clostridium Difficile Toxin A And B
JP2022535264A5Humanized Quadrispecific Octavalent Antibody Against Clostridium Difficile A-Toxin And B-Toxin
HK40072792AHumanized Tetra-Specific Octavalent Antibody Against Clostridium Difficile Toxin A And B
AU2020287324A1Humanized Tetra-Specific Octavalent Antibody Against Clostridium Difficile Toxin A And B
WO2022261455A3Genetically-Modified Saccharomyces Yeast Strains As Preventative And Therapeutic Agents
WO2022087021A1Neutralized Antibody And Method Of Use Thereof
WO2020247500A1Humanized Tetra-Specific Octavalent Antibody Against Clostridium Difficile Toxin A And B

What Technologies are Covered by Fzata?

The chart below distributes patents filed by Fzata in different countries on the basis of the technology protected in patents. It also represents the markets where Fzata thinks it’s important to protect particular technology inventions.

R&D Focus: How has Fzata search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Fzata?

Related Articles

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.